Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

被引：0
|
作者：
Piero Barbanti
Gabriella Egeo
Cinzia Aurilia
Florindo d’Onofrio
Maria Albanese
Ilaria Cetta
Paola Di Fiore
Maurizio Zucco
Massimo Filippi
Francesco Bono
Claudia Altamura
Stefania Proietti
Stefano Bonassi
Fabrizio Vernieri
机构：
[1] Headache and Pain Unit,Neurology Unit
[2] IRCCS San Rafaele Pisana,Regional Referral Headache CenterNeurology Unit
[3] San Rafaele University,Department of Systems Medicine
[4] San Giuseppe Moscati Hospital,Headache Unit, Department of Neurology
[5] University Hospital Tor Vergata,Headache Center, Neurlogy Unit
[6] University of Rome Tor Vergata,Neurology Unit, IRCCS San Rafaele Scientifc Institute
[7] Scientifc Institute San Rafaele Hospital,Headache and Neurosonology Unit
[8] Vita-Salute University,Department of Human Sciences and Quality of Life Promotion
[9] Headache Center,Headache and Neurosonology Unit
[10] ASST Santi Paolo Carlo,undefined
[11] San Camillo-Forlanini Hospital,undefined
[12] Vita-Salute San Raffaele University,undefined
[13] Center for Headache and Intracranial Pressure Disorders,undefined
[14] Neurology Unit,undefined
[15] A.O.U. Mater Domini,undefined
[16] Policlinico Universitario Campus Bio-Medico,undefined
[17] Clinical and Molecular Epidemiology,undefined
[18] IRCCS San Rafaele,undefined
[19] San Rafaele University,undefined
[20] Campus BioMedico University Hospital,undefined
来源：
The Journal of Headache and Pain | 2022年 / 23卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) (vol 23, 46, 2022)
    Barbanti, Piero
    Egeo, Gabriella
    Aurilia, Cinzia
    d'Onofrio, Florindo
    Albanese, Maria
    Cetta, Ilaria
    Di Fiore, Paola
    Zucco, Maurizio
    Filippi, Massimo
    Bono, Francesco
    Altamura, Claudia
    Proietti, Stefania
    Bonassi, Stefano
    Vernieri, Fabrizio
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [2] Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 24-week, multicenter, real-life, cohort study (the FRIEND study)
    Egeo, Gabriella
    Aurilia, Cinzia
    Torelli, Paola
    d'Onofrio, Florindo
    Laura, Di Clemente
    Finocchi, Cinzia
    Di Fiore, Paola
    Sette, Giuliano
    Vernieri, Fabrizio
    Grazzi, Licia
    Le Pera, Domenica
    Valenza, Alessandro
    Albanese, Maria
    Viticchi, Giovanna
    Proietti, Stefania
    Bonassi, Stefano
    Barbanti, Piero
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 100 - 101
  • [3] Fremanezumab in the prevention of high-frequency episodic and chronic migraine: FRIEND (FRemanezumab In rEal world stuDy), the first Italian multicenter, prospective real-life study
    Fofi, L.
    Egeo, G.
    Aurilia, C.
    Costa, C. M.
    Altamura, C.
    Vernieri, F.
    Albanese, M.
    D'Onofrio, F.
    Di Clemente, L.
    Zucco, M.
    Di Fiore, P.
    Frediani, F.
    Messina, R.
    Colombo, B.
    Filippi, M.
    Bono, F.
    Manzo, L.
    Carnevale, A.
    Barbanti, P.
    Proietti, S.
    Bonassi, S.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 171 - 172
  • [4] Fremanezumab in the prevention of high-frequency episodic and chronic migraine: Friend (fremanezumab in real world study), the first Italian multicenter, prospective real-life study
    Fofi, Luisa
    Egeo, Gabriella
    Aurilia, Cinzia
    Costa, Carmelina
    Altamura, Claudia
    Vernieri, Fabrizio
    Albanese, Maria
    D'Onofrio, Florindo
    Di Clemente, Laura
    Zucco, Maurizio
    Di Fiore, Paola
    Frediani, Fabio
    Messina, Roberta
    Colombo, Bruno
    Filippi, Massimo
    Bono, Francesco
    Manzo, Lucia
    Carnevale, Antonio
    Barbanti, Piero
    Proietti, Stefania
    Bonassi, Stefano
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 204 - 204
  • [5] Fremanezumab in the prevention of high-frequency episodic and chronic migraine: FRIEND (FRemanezumab In rEal world stuDy), the first Italian multicenter, prospective real-life study
    Fofi, L.
    Egeo, G.
    Aurilia, C.
    Costa, C. M.
    Altamura, C.
    Vernieri, F.
    Albanese, M.
    D'Onofrio, F.
    Di Clemente, L.
    Zucco, M.
    Di Fiore, P.
    Frediani, F.
    Messina, R.
    Colombo, B.
    Filippi, M.
    Bono, F.
    Manzo, L.
    Carnevale, A.
    Barbanti, P.
    Proietti, S.
    Bonassi, S.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 115 - 115
  • [6] Efficacy and safety of Fremanezumab in the preventive treatment of high-frequency episodic and chronic migraine: Russian real-life study
    Dobrynina, Larisa
    Afanasev, Maksim
    Belopasova, Anastasia
    Gubanova, Maria
    Baydina, Ekaterina
    CEPHALALGIA, 2023, 43 (1supp) : 221 - 222
  • [7] The First, Italian, Multicenter, Real-life Study with Erenumab in the Prevention of High Frequency Episodic and Chronic Migraine
    Barbanti, Piero
    Aurilia, Cinzia
    Cevoli, Sabina
    Colombo, Bruno
    Frediani, Fabio
    Bono, Francesco
    Grazzi, Licia
    D'Amico, Domenico
    Salerno, Antonio
    Mercuri, Bruno
    Carnevale, Antonio
    Vollono, Catello
    Egeo, Gabriella
    Fofi, Luisa
    Altamura, Claudia
    Costa, Carmen
    Brunelli, Nicoletta
    Fallacara, Adriana
    Pierangeli, Giulia
    Favoni, Valentina
    Messina, Roberta
    Filippi, Massimo
    Di Fiore, Paola
    Santangelo, Domenico
    Vernieri, Fabrizio
    NEUROLOGY, 2020, 94 (15)
  • [8] Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study
    Barbanti, Piero
    Aurilia, Cinzia
    Egeo, Gabriella
    Fofi, Luisa
    Cevoli, Sabina
    Colombo, Bruno
    Filippi, Massimo
    Frediani, Fabio
    Bono, Francesco
    Grazzi, Licia
    Salerno, Antonio
    Mercuri, Bruno
    Carnevale, Antonio
    Altamura, Claudia
    Vernieri, Fabrizio
    HEADACHE, 2021, 61 (02): : 363 - 372
  • [9] Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
    Vernieri, Fabrizio
    Altamura, Claudia
    Brunelli, Nicoletta
    Costa, Carmelina Maria
    Aurilia, Cinzia
    Egeo, Gabriella
    Fofi, Luisa
    Favoni, Valentina
    Pierangeli, Giulia
    Lovati, Carlo
    Aguggia, Marco
    d'Onofrio, Florindo
    Doretti, Alberto
    Di Fiore, Paola
    Finocchi, Cinzia
    Rao, Renata
    Bono, Francesco
    Ranieri, Angelo
    Albanese, Maria
    Cevoli, Sabina
    Barbanti, Piero
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [10] GalcanezumAb for prevention of high frequency episodic and chronic migraine in the Real Life in ITaly: a multicenter prospective cohort study (the GARLIT study)
    Vernieri, F.
    Altamura, C.
    Brunelli, N.
    Costa, C. M.
    Aurilia, C.
    Egeo, G.
    Fofi, L.
    Favoni, V.
    Pierangeli, G.
    Lovati, C.
    Aguggia, M.
    Bertuzzo, D.
    D'Onofrio, F.
    Doretti, A.
    Di Fiore, P.
    Frediani, F.
    Finocchi, C.
    Rao, R.
    Di Cola, F. Schiano
    Bono, F.
    Ranieri, A.
    Albanese, M.
    Cevoli, S.
    Barbanti, P.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 29 - 30
12345